Nintedanib: New Oral Angiogenesis Inhibitor in Lung Cancer Nintedanib: New Oral Angiogenesis Inhibitor in Lung Cancer

When added to docetaxel in second-line therapy, the new agent improved survival in a subgroup of patients with adenocarcinoma histology. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news